邮箱：zhoujinming@zjnu.edu.cn
周金明:校“双龙****”****。1977年9月出生，2000年本科毕业于北京师范大学化学系，2003年硕士毕业于北京师范大学化学系，研究方向为核医药化学；2006年7月博士毕业于中科院上海有机化学研究所，研究方向计算辅助药物设计；2006年11月至2009年11月在加拿大Mcgill University 医学院Lady Davis Institute从事博士后研究，主要从事基于雄激素受体（AR）结构的AR拮抗剂的药物设计，发展了系列具有全新骨架雄激素受体拮抗剂，在博士后期间，还获得过的癌症治疗方面的Fellowship (MCETC/ FRSQ / CIHR Strategic training program in Cancer Experimental Therapeutics)。2010年1月-2018年7月在北京协和医学院医药生物技术研究所工作。2018年8月至今到浙江师范大学任教，研究主要聚焦基于蛋白质结构分析及基于蛋白结构的药物分子设计。目前已主持国家自然基金(4项)，重大新药创制子任务（1项），人事部回国留学人员基金(1项), 医科院院所长基金（1项），2012年入选了医科院“协和新星”计划，医科院创新工程子项目负责人等，并参与973课题一项，2014协和创新团队学术骨干。至今发表论文50余篇，其中SCI论文40余篇, 作为责任作者或第一作者的论文包含了国际药物化学主要SCI期刊如J Med Chem, Eur J Med Chem，Bioorg Med Chem Lett,等, 其他论文包括Cell Host & Microbe, PLOS Pathogens ,JCTC, 及J Cheminf等。目前获得多个抗病毒、抗肿瘤先导化合物，申请及授权专利8项。
研究方向：

基于蛋白质靶点结构的药物分子设计，尤其是针对癌症和HIV-1等重大疾病的重要靶点，以及基于结构的先导化合物的优化等;
肿瘤免疫小分子药物的开发，尤其是针对免疫检测点（Immune checkpoint）蛋白PD-1/PD-L1等靶点；
重要药物分子的合成路线优化改造，医药中间体合成以及其他工艺研究。
非常感谢对我们研究方向感兴趣的各位研究生并欢迎加入我们实验室团队。联系方式：zhoujinming@zjnu.edu.cn


科研项目：
[1] 国家自然科学基金面上项目(**), 基于雷公藤单体雷酚内酯发展治疗去势抵抗前列腺癌（CRPC）的新策略. 2017.1-2020.12. 主持
[2] 基于宿主限制因子等关键病原宿主相互作用的病毒传染病新型靶标发现和评价重大新药创制子任务2018. 1-2020.12 主持
[3] 功能分子结构分析医科院创新工程子项目2017-2020 主持
[4] 国家自然科学基金面上项目(**), HIV-1宿主限制因子BST-2和拮抗蛋白Vpu的相互作用研究. 2013.1-2016，结题主持.
[5] 国家自然科学基金交流合作项目(FRQS-NSFC合作交流, ), 利用传统中医资源寻找非小细胞肺癌的新疗法, 2013.1-2013.12, 结题主持.
[6] 国家自然科学基金青年基金(**), 基于雄激素受体结构的抗前列腺癌药物合理设计. 2011.1-2013.12, 结题主持.
[7] 留学人员科技活动项目择优资助,靶向Vif-APOBEC3G作用面抗HIV-1先导化合物优化. 2012.1-2012.12, 结题主持.
[8] 中央级公益性科研院所基本科研业务专项, 基于BST-2/Vpu/β-TrCP三分子结合模式的抗HIV-1药物研究, 2010.5-2012.5, 结题主持.
[9] 北京协和医学院, 中国医学医科院“协和新星”计划, 2012年, 结题主持.
[10] 2012年国家重大科学研究计划(973计划), 病毒与宿主细胞相互作用分子机制的研究(子课题), 主要学术骨干. 结题
[11] 2014年度协和创新团队, 主要学术团队成员. 结题

发表文章：[1] Meng Wu, Yongli Xie, Xiangling Cui, Chenchao Huang, Rongyu Zhang,Yang He, Xiaoyu Li, Mingliang Liu, Shan Cen, Jinming Zhou Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist. European Journal of Medicinal Chemistry 2019, 166 2019 232-242.
[2] Jiwei Ding, Ling Ma, Jianyuan Zhao, Yongli Xie, Jinming Zhou, Xiaoyu Li and Shan Cen An integrative genomic analysis oftranscriptional profiles identifies characteristic genes andpatterns inHIV-infected long-term non-progressors andelite controllers. Journal of Translational Medicine 2019 17:35
[3] Liu Yangguang, Wu Meng, Wang Tianqi, Xie Yongli, Cui Xiangling, He Liujun, He Yang, Li Xiaoyu, Liu Mingliang, Hu Laixing, Cen Shan, Zhou Jinming (通讯作者) Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding SiteFrontiers in Pharmacology 2018(9), 1419-1429.
[4] Ding J, Zhao J, Zhou J, Li X, Wu Y, Ge M, Cen S. Association of gene polymorphism of SDF1(CXCR12) with susceptibility to HIV-1 infection and AIDS disease progression: A meta-analysis. PLoS One. 2018 13(2):e**.
[5] Wang J, Wang Y, Zhou R, Zhao J, Zhang Y, Yi D, Li Q, Zhou J, Guo F, Liang C, Li X, Cen S. Host Long Noncoding RNA lncRNA-PAAN Regulates the Replication of Influenza A Virus. Viruses. 2018 10(6). pii: E330.
[6] Yi DR, An N, Liu ZL, Xu FW, Raniga K, Li QJ, Zhou R, Wang J, Zhang YX, Zhou JM, Zhang LL, An J, Qin CF, Guo F, Li XY, Liang C, Cen S. Human MxB Inhibits the Replication of Hepatitis C Virus. J Virol. 2018 93(1). pii: e01285-18.
[7] Li Quanjie , Ma Ling , Yi Dongrong , Wang Han , Wang Jing , Zhang Yongxin , Guo Ying , Li Xiaoyu , Zhou Jinining* （共同通讯）, Shi Yi* , Gao George F. , and Cen Shan*. Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein, Antiviral Res. 2018, 155, 1-11.
[8] Ling Ma, Zhixin Zhang, Zhenlong Liu, Qinghua Pan, Jing Wang, Xiaoyu Li, Fei Guo, Chen Liang, Laixing Hu, Jinming Zhou* （共同通讯），Shan Cen*.Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation Scientific Reports. 2018, 8,8067.
[9] Congjie Zhai , Ling Ma et al Jinming Zhou*(共同通讯), Shan Cen* Identification and characterization of loop7 motif and its role in regulating biological function of human APOBEC3G through molecular modeling and biological assay Acta Pharmaceutica Sinica B 2017;7(5):571–582 (SCI)
[10] Yong-Xin Zhang, Yu-Ming Huang, Quan-Jie Li, Xiao-Yu Li, Yong-Dong Zhou, Fei Guo, Jin-Ming Zhou*(共同通讯), Shan Cen* A highly conserved amino acid in VP1 regulates maturation of enterovirus 71 PLOS Pathogens h 2017,13(9):e** .
[11] Chao Chen, Meng Wu, Shan Cen, Jianhui Wu and Jinming Zhou (通讯作者)MTLD, a Database of Multiple Target Ligands, the Updated VersionMolecules2017,22(9), 1375. (SCI, IF 2.9).
[12] Xu J,Wang JX, Zhou JM,Xu CL, Huang B, Xing Y, Wang B, Luo R, Wang YC,You XF, Lu Y, Yu LY A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity Scientific Reports2017, 7(1):5093 (SCI, JCR 1区, IF 4.26).
[13] Ding J,Zhao J,Yang Z,Ma L,Mi Z,Wu Y,Guo J,Zhou J,et al MicrobialNaturalProductAlternariol5-O-MethylEtherInhibitsHIV-1IntegrationbyBlocking NuclearImportof thePre-IntegrationComplex. Viruses.2017 10;9(5). pii: E105. doi: 10.3390/v**.
[14] Yang He, Meng Wu, Yangguang Liu, Quanjie Li, Xiaoyu Li, Laixing Hu,* Shan Cen,* and Jinming Zhou# (通讯作者) Identification of Triptophenolide from Tripterygium wilfordii as a Panantagonist of Androgen Receptor ACS Med. Chem. Lett. 2016 ACS Med Chem Lett. 2016 Sep 28;7(12):1024-1027.
[15] Zhou Jinming*,Li Quanjie, Wu Meng, Chen Chao, Cen Shan. Progressin therationaldesignforpolypharmacologydrug.Curr Pharm Des. 2016;22(21):3182-9. .
[16] 何阳，刘阳光，丁寄葳，李晓宇，岑山，周金明# (通讯作者).以雄激素受体为靶标的抗前列腺癌药物筛选模型的建立和应用药学学报2016, 51(2): 287-293.
[17] Li Q, Fan S, Li X, Jin Y, He W, Zhou J (共同通讯), Cen S, Yang Z. Insights into the Phosphoryl Transfer Mechanism of Human Ubiquitous Mitochondrial Creatine Kinase. Sci Rep. 2016 Dec 2; 6:38088.
[18] Q Zhang, Z Mi, Y Huang, L Ma, J Ding, J Wang, Y Zhang,J Zhou, F Guo, X Li*, S Cen*. 2-thio-6-azauridine Inhibits Vpu Mediated BST-2 Degradation. Retrovirology. 2016;13(1):13.
[19] Zheng YB, Gong JH, Liu XJ, Wu SY, Li Y, Xu XD, Shang BY, Zhou JM, Zhu ZL, Si SY, Zhen YS. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity Sci Rep. 2016; 6:31472.
[20] Chao Chen, Yang He, Jianhui Wu,Jinming Zhou# (通讯作者) Creation of a free, Internet-accessible database: the Multiple Target Ligand Database. Journal of Cheminformatics 2015, 7:14.
[21] Xiaohong Tian, Yang He, Jinming Zhou# (通讯作者)Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Frontiers in Pharmacology2015, Vol6, 57.
[22] 何阳，刘阳光，岑山，周金明# (通讯作者).前列腺癌耐药机制的研究进展.药学学报. 2015, 50 (7): 797 ?801.
[23] Lexing Xu, Xin Wang, Hongwei He, Jinming Zhou,Xiaoyu Li, Hongtao Ma,Zelin Li,Yi Zeng,Rongguang Shao,*Shan Cen,*,Yucheng Wang*,structure-Based Design of Novel Chemical Modification of the 3′-Overhang for Optimization of Short Interfering RNA Performance Biochemistry 2015, 54, 1268-1277.
[24] Li, Fengwen Xu, Siqi Hu, Jinming Zhou, Shan Mei, Xiaoxiao Zhao, Shan Cen, Qi Jin, Chen Liang, Fei Guo. Characterization of the interactions between SIVrcm Vpx and red-capped mangabey . Biochem J. 2015, 468(2), 303-13.
[25] Zeyun Mi, Xin Wang, Yang He, Xiaoyu Li, Jiwei Ding, Hongyun Liu, Jinming Zhou# (共同通讯作者), Shan Cen A novel peptide to disrupt the interaction of BST-2 and Vpu Biopolymers (Pept Sci) 2014, 102, 280–287.
[26] Xin Wang, Xiaoyu Li, Jing Ma, Li Zhang, Ling Ma, Zeyun Mi, Jinming Zhou, Fei Guo, Lawrence Kleimanb, Shan Cen. Human APOBEC3F incorporation into human immunodeficiency virustype 1 particles. Virus Research2014, Vol191, P30–38.
[27] Weiguo Liu,Jinming Zhou, Guoyan Geng, Rongtuan Lin, Jian Hui Wu Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB Investigational New Drugs 2014, Vol 32(2), 227-234.
[28] Zhixin Zhang, Congjie Zhai, Zeyun Mi, Jiwei Ding, Yongxin Zhang, Xing Shi, Xiaoyu Li, Liyan Yu, Zhuorong Li, Jiandong Jiang, Jinming Zhou# (共同通讯作者), Shan Cen* Molecular modeling of Human A3G to predict the binding modes of the inhibitor compounds IMB26 and IMB35. Acta Pharmaceutica Sinica B, 2013, 3, 239-244.
[29] Xiaojing Pang, Siqi Hu, Jian Li1, Fengwen Xu, Shan Mei1, Jinming Zhou, Shan Cen, Qi Jin* and Fei Guo* Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu Retrovirology 2013, 10, 84.
[30] Zhenlong Liu, Qinghua Pan, Shilei Ding, Jin Qian, Fengwen Xu,Jinming Zhou, Shan Cen, Fei Guo and Chen Liang The interferon-inducible MxB protein inhibits HIV-1 infection The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host & Microbe, 2013, 14(4):398-410.
[31] Zhang YX, Wei T, Li XY, Yin X, Li YH, Ding JW, Zhou JM,Zhang GZ, Jin Q, Cen S: Construction and characterization of an infectious cDNA clone of enterovirus type 71 subgenotype C4. Virus Genes 2013, 47(2):235-243.
[32] Ma J, Li X, Xu J, Zhang Q, Liu Z, Jia P, Zhou J, Guo F, You X, Yu L et al: The roles of APOBEC3G complexes in the incorporation of APOBEC3G into HIV-1. PloS one 2013, 8(10):e74892.
[33] Jinming Zhou# (共同通讯作者), Zhixin Zhang, Zeyun Mi, Xin Wang, Quan Zhang, Xiaoyu Li, Chen Liang, and Shan Cen#. Characterization of the interface of BST-2/Vpu protein complex via computational chemistry. Biochemistry, 2012, 51, 1288-1296.
[34] Yang ZHANG*, Jinming ZHOU* (共同第一作者), Ming CHANG*, Liping BAI, Junjie SHAN, Chen YAO, Rong JIANG, Lian-hong GUO, Ren ZHANG, Jian-bo WU, Yuan LI. Characterization and functional evidence for Ste27 of Streptomyces sp. 139 as a novel spermine/spermidine acetyltransferase. Biochemical Journal. 2012, 443(3), 727-34.
[35] Weiguo Liu, Jinming Zhou, Guoyan Geng,Qingwen Shi,Francoise Sauriol, Jian Hui Wu.Antiandrogenic, maspin induction and anti-prostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A. Journal of Medicinal Chemistry, 2012, 55(2), 971-975.
[36] Quan Zhang, Zhenlong Liu, Xiaoyu Li, Zeyun Mi, Pingping Jia, Jinming Zhou, Xuefu You, Liyan Yu, Fei Guo, Jing Ma, Chen Liang, Qi Jin, Jiandong Jiang, Shan Cen. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2. Antiviral Research, 2011, 91(3), 321-329.
[37] Xiaoyu Li, Jing Ma, Quan Zhang, Jinming Zhou, Liyan Yu, Fei Guo, Qi Jin, Lixun Zhao, Yi Zeng, Shan Cen. Functional analysis of two cytidine deaminase domains in APOBEC3G. Virology, 2011, 414 (2), 130-6.
[38] Jin-Ming Zhou, Guo-Yan Geng, Gerald Batist,Jian-Hui Wu*. Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Investigational New Drugs, 2010, 28(3), 291-298.
[39] Jin-Ming Zhou, Bing Liu, Jian-Hui Wu*. Study of the impact of the T877A mutation on ligand- induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens. Proteins, 2010, 78, 623-637.
[40] Jin-Ming Zhou, Guoyan Geng, Qingwen Shi, Francoise Sauriol, Jian Hui Wu*. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming anti-androgen resistance. Journal of Medicinal Chemistry, 2009, 52 (17), 5546-5550. (SCI, JCR 1区, IF 5.614)
[41] Jin-Ming Zhou, Guo-Yan Geng, Gerald Batist, Jian-Hui Wu*. Syntheses and potential anti-prostate cancer activities of ionone-based chalcones. Bioorganic & Medicinal Chemistry Letters, 2009, 19, 1183–1186.
[42] Jin-Ming Zhou, Jun-Hong Zhou, Hua-Bei Zhang, Xi-Cheng Dong and Min-Bo Chen*. The different position fluoro-substitution effect of fluoro D-glucoses comparing to D-glucose: Random conformational search and Quantum chemical calculation. Carbohydrate Research, 2006, 341, 2224-2232.
[43] Jin-Ming Zhou, Jun-Hong Zhou, Yi Meng and Min-Bo Chen*. Molecular dynamics simulation of iminosugar inhibitor-glycosidase complex: Insight into the binding mechanism of 1-deoxynojirimycin and isofagomine towardsβ-glucosidase. Journal of Chemical Theory and Computation, 2006, 2, 157-165.
申请专利
[1] Jian Hui Wu*, Weiguo Liu, Jinming Zhou,Guoyan Geng. Novel Tanshinone derivatives as anticancer agents, U.S. Provisional B&P File No. (in progress).
[2] Jian-Hui Wu*, Gerald Batist, Jin-Ming Zhou, Guo-Yan Geng. Hybrid molecules of dietary agents as anticancer agents, U.S. Provisional B&P File No. 14657-32.
[3] 周金明，何阳，李晓宇，岑山等雷酚内酯作为雄激素受体拮抗剂的应用申请号: 1.6
[4] 岑山, 张全, 李晓宇, 魏晓露, 刘振龙, 贾平平, 周金明.抑制Vpu下调BST2的抗HIV药物筛选方法, 申请号: 2.1.
[5] 贾平平, 张义, 李晓宇, 周金明, 殷霄, 岑山^*. 一种抗结核药物高通量筛选模型的构建方法. 申请号: 2.6.
[6]周金明马铃张志鑫李晓宇岑山IMB-301制备抗病毒药物中的应用申请号: 20**
[7]周金明，刘阳光，李晓宇，岑山等IMB-A6作为雄激素受体拮抗剂的应用申请号: 20**
[8] 周金明，吴萌，张荣玉，黄晨超，李晓宇，岑山ZJU-IMB-Z19化合物在治疗前列腺癌中的应用申请号：3.6.
非常感谢对我们研究方向感兴趣的各位研究生并欢迎加入我们实验室团队。联系方式：zhoujinming@zjnu.edu.cn或zhou_jim@hotmail.com